With the implementation of new HER2-targeting therapies for breast cancer [40] and the emergence of trials investigating the antibody drug conjugate trastuzumab deruxtecan targeting HER2-low EBC [41], similar analyses to those in the present study should be conducted to evaluate potential effects of new HER2 therapies on micrometastases and their impact on survival. Here, ERBB2 is linked to breast cancer.